Protocol Title:  A Prospective, Phase II Trial of Molecular Profiling to Guide Neoadjuvant 
Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas 
 
[STUDY_ID_REMOVED] 
 Date:  June 28, 2018  
A Prospective, Phase II Trial of Molecular Profiling to Guide Neoadjuvant Therapy for 
Resectable and Borderline Resectable Adenocarcinoma  of the Pancreas  
 
June 28, 2018 / Amendment  18 
INVESTIGATORS:   
Principal Investigators :  Kathleen K. Christians, MD, FACS,  
Susan Tsai MD, MHS,  
Paul Ritch MD  
Douglas B. Evans, MD Medical College of Wisconsin  
[ADDRESS_1028343]. 
Milwaukee, WI  [ZIP_CODE] 
 
CO-INVESTIGATORS:  
 Edward Quebbeman, MD, PhD  
Bryan Hunt, MD James Thomas, MD, PhD 
Kulwinder Dua, MD Beth Erickson, MD, FACR 
Abdul Khan, MD Tracy Kelly, MD  
Ben George, MD Syed A. Ahmad, MD 
Kiran Turaga, MD, MPH T. Clark Gamblin, MD, MS 
W. Dennis Foley, MD A. Craig Mackinnon, MD, PhD 
Robert Hellman, MD Paul Knechtges, MD 
 Study Coordinator: 
For Medical College of Wisconsin:  
Haley Heaviland [ADDRESS_1028344] 
Milwaukee, WI    [ZIP_CODE] 
Phone [PHONE_15657] Fax:  [PHONE_15658] 
[EMAIL_14346]
 
 
 
 
  
June 28 2018, Amendment 18 2 For University of Cincinnati: 
Alison Kastl, BS, CCRC  
Director of Clinical Trials  
University of Cincinnati Cancer Institute  
[ADDRESS_1028345] Cincinnati, OH [ZIP_CODE] Phone [PHONE_15659] 
Fax [PHONE_12443] 
Email [EMAIL_14347]
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
June 28 2018, Amendment 18 3 CLINICAL STUDY PROTOCOL  
Protocol Number = MCW  PRO [ZIP_CODE];  
A Prospective, Phase II Trial of Molecular Profiling to Guide Neoadjuvant Therapy for 
Resectable and Borderline Resectable Adenocarcinoma of the Pancreas  
 
 
 
 
 
Indication:  Resectable and Borderline Resectable Pancreatic Cancer  
Phase:  Phase II  
 
 
 
 
 
   
 
 
 
 
This is an investigator-initiated study.  The principal investigator [INVESTIGATOR_751162], MD (who 
may also be referred to as the sponsor-investigator), is conducting the study and acting as the 
sponsor.  Therefore, the legal/ethical obligations of the principal investigator [INVESTIGATOR_20531] a sponsor and those of an investigator. 
 
 
June 28 2018, Amendment 18 4 PROTOCOL SUMMARY   
Study Title:   A Prospective, Phase II Trial of Molecular Profiling to Guide Neoadjuvant 
Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas  
Phase:   Phase II  
Number of Patients:  130 patients  
Study Objectives  
Primary Objectives:  
1. To compare the resectability rate (percent of all patients completing therapy to include 
surgical resection) using a neoadjuvant treatment regimen selected by [CONTACT_751183]. 
Secondary  Objectives:  
1. To compare overall survival (OS) rates of resectable and borderline resectable pancreatic cancer patients treated with molecularly targeted neoadjuvant therapy 
followed by [CONTACT_751184].  
2. To compare progression- free survival (PFS) rates of patients with resectable and 
borderline resectable pancreatic cancer treated with molecularly targeted neoadjuvant therapy followed by [CONTACT_751185].  
3. To determine the frequency with which molecular profiling of a patient’s tumor by [CONTACT_751186] a target for an approved, commercially -available chemotherapeutic regimen.  
4. To compare the molecular profile of pretreatment biopsies and resected tumors. We will 
compare the molecular profile obtained at time of diagnosis (FNA) with the molecular profile obtained from the resected specimen.  
5. To determine the extent of histologic tr eatment response to targeted chemotherapeutic 
regimens in resected tumors.*  
6. To determine the prognostic relevance of radiological response among patients 
undergoing neoadjuvant therapy. 
7. To determine the ability to generate primary xenografts of pancreatic cancer from 
resected tumors.*  
8. To compare quality and outcomes of both patterns of recurrence and ultimately survival 
in patients who receive radiation therapy at FH/MCW versus other institutions.    
Overview of Study Design:    
This is a phase II study for resectable and borderline resectable pancreatic cancer which  utilizes molecular profiling of tissue samples from the pancreatic cancer (obtained either through EUS/FNA 
biopsy at the time of diagnosis or from the surgical specimen) to gu ide chemotherapy selection.  
June 28 2018, Amendment 18 5 Study Population:    
Resectable Pancreatic Cancer (defined by):  
1. No evidence of extra pancreatic disease  
2. No evidence of tumor -arterial abutment (celiac, SMA or HA)  
3. If tumor induced narrowing of the SMV, PV, or SMV-PV confluence is present, it must be 
<50% of the diameter of the vessel  
4.   Ca 19 -9 <5000, when bilirubin is <2 
 
Borderline Resectable Pancreatic Cancer (to include at least one of the following):  
1. Tumor abutment <180° of the SMA or celiac axis 
2. Tumor abutment or encasement of a short segment of the HA  
3.  Tumor induced narrowing of SMV, PV or SMV- PV of >50% of the diameter of the vessel.  
4. Short segment occlusion of the SMV, PV or SMV-PV with a suitable PV above and SMV 
below, for reconstruction  
5. CT or MRI findings susp icious for, but not diagnostic of, metastatic disease (based on 
review at each site’s weekly multidisciplinary pancreatic cancer conference)  
6. Biopsy proven N1 disease (regional lymph nodes involved) from pre- referral biopsy or 
EUS -guided FNA 
7. Resectable tum or and CA 19-9 >5000 
 
Inclusion criteria:  
Eligibility for Screening consent:  
1. Have adenocarcinoma of the pancreas or highly suspi[INVESTIGATOR_751163]  
2. [ADDRESS_1028346] LAR Legally Authorized Representative  
Eligibility for Treatment  consent ,: 
1. Histologic diagnosis of pancreatic adenocarcinoma  
2. Have an ECOG performance status < [ADDRESS_1028347] or MRI 
findings  
4.  Total leukocytes >3 x103/μL 
June 28 2018, Amendment 18 6 5.  Absolute neutrophil count (ANC) >1.5x 103/μL 
6.  Hemoglobin > 9 g/dL  
7.  Platelets >100 x 10e3/μL  
8.  Creatinine clearance > 60 mL/min or creatinine <1.5 mg/dL  
9. Total  bilirubin < 2 mg/dL:  At two weeks from biliary decompression, if the subject’s 
serum bilirubin  remains greater than two, but has demonstrated a progressive decline, the 
subject may be enrolled into the trial  and appropriate modification and dose adjustments 
will be made to the predicted regimen.  
 
Exclusion Criteria:  
1. Have received chemotherapy or chemoradiation within  [ADDRESS_1028348] any previous history of another malignancy (other than cured basal or squamous cell 
carcinoma of the skin or cured in-situ carcinoma of the cervix) within [ADDRESS_1028349]- feeding patients or any patient with ch ild-bearing potential not using 
contraception 4 weeks prior to treatment  
Duration of Study:   Accrual period: Approximately 48 months. 
 
  
June 28 2018, Amendment 18 7 Table of Contents  
TITLE PAGE  .............................................................................................................................................................. 1 
PROTOCOL SUMMARY ..................................................................................................................................... 4  
ABBREVIATIONS  .............................................................................................................................................. 12 
1. INTRODUCTION  ............................................................................................................................................ 14 
1.1. Background  ......................................................................................................................................... 14 
1.2. Proposed Therapeutic Intervention  .................................................................................................... 15 
2. OBJECTIVES AND STUDY DESIGN ....................................................................................................... 15 
2.1. Objectives  ............................................................................................................................................ 15 
2.1.1. Primary Objective  .............................................................................................................................. 15 
2.1.2. Secondary Objectives  ........................................................................................................................ 15 
2.2. Study Design  ........................................................................................................................................ 16 
2.2.1. Treatment Strategy  ............................................................................................................................ 18 
TABLE 1:  .............................................................................................................................................. 20 
2.2.2. [Neoadjuvant] Pre -operative Pathway for Resectable Patients  .......................................................... 21 
2.2.3. [Neoadjuvant] Pre -operative Pathway for Borderline Resectable Patients  ........................................ 22 
2.2.4. [Neoadjuvant] Preoperative Treatment  .............................................................................................. 23 
[IP_ADDRESS] [Neoadjuvant] Preoperative FNA Profiling Schema  ................................................................ 23 
[IP_ADDRESS]. [Neoadjuvant] Preoperative Treatment Regimens  ................................................................. 23 
a. Gemcitabine- based XRT Treatment Regimen:  .................................................................. 23 
b. Capecitabine- based XRT Treatment Regimen:  .................................................................. 23 
c. FOLFIRINOX Treatment Regimen:  .................................................................................. 23 
d. FOLFIRI Treatment Regimen:  ........................................................................................... 23 
e. Gemcitabine w/irinotecan Treatment Regimen:  ................................................................. 23 
f. Gemcitabine w/ oxaliplatin Treatment Regimen:  ............................................................... 24 
June 28 2018, Amendment 18 8 g. Gemcitabine w/ cisplatin Treatment Regimen: .................................................................. 24 
h. Gemcitabine/capecitabine Treatment Regimen:  ................................................................. 24 
i. Gemcitabine/nab -paclitaxel Treatment Regimen:  ............................................................... 24 
j. Capecitabine/nab -paclitax el Treatment Regimen:  .............................................................. 24 
[IP_ADDRESS]. Disease Progression on Therapy  ............................................................................................ 24 
2.2.5. [Adjuvant] Pathways for all patients after Postoperative Restaging .................................................. 25 
2.2.6. [Adjuvant] Postoperative Treatment  .................................................................................................. 25 
[IP_ADDRESS]  [Adjuvant] Postoperative Profiling Schema no prior XRT  .................................................... 25 
[IP_ADDRESS]  [Adjuvant] Postoperative Profiling Sche ma when patient DID receive pre -operative XRT  . 25 
[IP_ADDRESS].  [Adjuvant] Postoperative Treatment Regimens  .................................................................... 25 
a. Gemcitabine- based XRT Treatment Regimen:  .................................................................. 25 
b. Capecitabine- based XRT Treatment Regimen:  .................................................................. 26 
c. FOLFIRINOX Treatment Regimen:  .................................................................................. 26 
d. FOLFIRI Treatment Regimen:  ........................................................................................... 26 
e. Gemcitabine w/ irinotecan Treatment Regimen:  ................................................................ 26 
f.. Gemcitabine w/ oxaliplatin Treatment Regim en: .............................................................. 26 
g. Gemcitabine w/ cisplatin Treatment Regimen: .................................................................. 26 
h. Gemcitabine/capecitabine Treatment Regimen:  ................................................................. 26 
i. Gemcitabine/nab -paclita xel Treatment Regimen:  ............................................................... 27 
j.  Capecitabine/nab -paclitaxel Treatment Regimen:  ............................................................. 27 
k. Gemcitabine alone Treatment Regimen:  ............................................................................ 27 
l. Capecitabine alone Treatment Regimen:  ............................................................................ 27 
m. 5FU alone Regimen:  ......................................................................................................... 27 
n. No further treatment recommended:  .................................................................................. 27 
2.2.7. Outcome Measures  ............................................................................................................................ 27 
3. PATIENT SELECTION ................................................................................................................................. 28 
3.1. Screening and Eligibility Criteria  ....................................................................................................... 28 
June 28 2018, Amendment 18 9 3.1.1. T reatment Eligibility Criteria: ........................................................................................................... 28 
3.1.2.Definition of Resectable Pancreatic Cancer includes all of the following: ......................................... [ADDRESS_1028350] profiled therapy  ................................. 32 
6.3.5 Radiation Therapy Data Review………………………………………………………….[ADDRESS_1028351] Imaging  ........................................................................................................................................ 36 
7.2.2. PET -Scan Imaging  ............................................................................................................................. 36 
7.2.3. Diffusion Weighted MRI Imaging  ..................................................................................................... 36 
June 28 2018, Amendment 18 10 7.2.4. Biochemical Testing  .......................................................................................................................... 37 
7.3. Survival  ............................................................................................................................................... 37 
8. ASSESSMENT OF SAFETY, RISKS, AND BENEFITS ....................................................................... 37 
8.1. Adverse Events  .................................................................................................................................... 37 
8.1.1 Recording Adverse Events  ................................................................................................................. 37 
8.1.2 Reporting Adverse Events (AE)  ......................................................................................................... 38 
8.2. S erious Adverse Events (SAEs)  ........................................................................................................... [ADDRESS_1028352] Xenograft Tumors  ........................................................................................... 41 
12.1.1. Rationale  .......................................................................................................................................... 41 
12.1.2. Murine Model  .................................................................................................................................. 42 
12.2. Characterization of Resected Primary & Metastatic Tumors  .......................................................... 42 
12.2.1. Rationale  .......................................................................................................................................... 42 
12.2.2. Molecular Characterization of Primary Resected and Metastatic Tumors  ...................................... 42 
12.2.3. Biomarkers in peripheral blood  ....................................................................................................... 43 
13. ADMINISTRATION  ..................................................................................................................................... 43 
13.1. Trai ning  ............................................................................................................................................. 43 
June 28 2018, Amendment 18 11 13.2. Multi -site Approval and Activation  .................................................................................................. 43 
13.2.1 Site Initiation  .................................................................................................................................... 44 
13.2.2 Monitoring  ........................................................................................................................................ 44 
13.3 Modif ication of the Protocol  ............................................................................................................... 44 
13.4. Completion of Case Report Forms  .................................................................................................... 44 
13.5 Access to Source Data and Study Documents  .................................................................................... 44 
13.6. Data Safety Monitoring ..................................................................................................................... 45 
13.7. Retention of Study Documentation  ................................................................................................... 46 
13.8. Ethics Consideration  ......................................................................................................................... 46 
13.9. Publication Policy  .............................................................................................................................. 47 
FIGURE A  ................................................................................................................................................................ 48 
FIGURE B  ................................................................................................................................................................ 49 
FIGURE C  ................................................................................................................................................................ 50 
FIGURE E ................................................................................................................................................................ 52 
APPENDICES A – M (SEE SEPARATE APPENDICES DOCUMENT)  .............................................. 53 
14. REFERENCES  ............................................................................................................................................... 54 
  
  
  
June 28 2018, Amendment 18 12 ABBREVIATIONS  
 
ADC   apparent diffusion coefficient 
ALKP   alkaline phosphatase 
ALT/SGPT  alanine transaminases  
ANC   absolute neutrophil count 
APTT   activated partial thromboplastin time  
AST/SGOT  aspartate transaminases  
CR  complete response 
CRF   case report form  
CT  computed tomography 
CTCAE  common toxicity criteria for adverse events 
ECOG  Eastern Cooperative Oncology Group 
ERCC1  Excision Repair Cross- Complementation [ADDRESS_1028353]  
HA   hepatic artery  
hENT1   human equilibrative nucleoside transporter 1 
HIV  human immunodeficiency virus 
HBV  hepatitis B virus  
HCV  hepatitis C virus  
HPB   hepato -pancreatico -biliary  
IHC/FISH  immunohistochemistry/fluorescence in situ hybridization (IHC/FISH)  
LDH  lactate dehydrogenase  
MPI  [INVESTIGATOR_751164]  
N1  regional lymph nodes positive for tumor 
NCI  national cancer institute  
June [ADDRESS_1028354]  response evaluation criteria in solid tumors 
RPMI   Roswell Park Memorial Institute (media)  
RRM1   ribonucleotide reductase M1  
SD  stable disease  
SMA    superior mesenteric artery  
SMV   superior mesenteric vein  
SPARC  Secreted Protein And Rich in Cysteine 
SUV  Standar dized Uptake Value  
TOP1   Topoisomerase [ADDRESS_1028355]   upper limits of normal 
XRT   radiation  
June 28 2018, Amendment 18 14 1. INTRODUCTION  
   1.1. Background 
 Pancreatic cancer is the fourth leading cause of cancer death in the [LOCATION_002]. There we re 43,140 
estimated new cases of pancreatic cancer in 2010 and 36,800 will succumb to this disease . Despi[INVESTIGATOR_751165], diagnostics,  and perioperative and intraoperative care, the actual 5 -year 
survival rate of patients with small tumors, no lymphadenopathy and who are completely resected 
remai ns <30% .[ADDRESS_1028356] led clinicians to search for new modalities and/or 
sequencing of therapy as part of a multidisciplinary approach to pancreatic cancer treatment .  
 Neoa djuvant, as opposed to adjuvant , therapy allows delivery of therapy to a well- vascularized tumor , 
ensuring that the drug can reach the tumor . It allows for the completion of therapy prior to surgery to 
prevent patient drop- out due to perioperative complication . Neoadjuvant therapy also a cts as a selection 
tool for optimal surgical candidates by [CONTACT_751187] . Indeed, the recent report of gemcitabine-based 
preoperative (neoadjuvant ) therapy has demonstrated the most favorable patient survival reported in a 
prospective trial.
[ADDRESS_1028357] HER2/neu in breast cancer, and bevacizumab against VEGF and tyrosine kinase inhibitors against GIST tumors . In contrast  to indiscriminate application s of 
chemotherapy, targeted therapi[INVESTIGATOR_751166] . Similarly, in pancreatic cancer, the identification of key molecular targets may 
increase the efficacy of existing systemic agents by [CONTACT_751188].   The most common chemotherapeutic agents used in pancreatic cancer include gemcitabine , platinum 
agents, irinotecan, and 5- fluorouracil (5- FU) de rivatives. In  review of the literature, six specific molecular 
targets have been identified which are predictive of chemo sensitivity to these agents in in vitro  and in 
vivo models . Specifically, low thymidylate synthase (TYMS) levels predict efficacy of 5 -FU-based 
therapi[INVESTIGATOR_751167].  Excision repair cross- complemen ting (ERCC1) protein repairs DNA damage 
caused by [CONTACT_751189]. As a result, low ERCC1 protein levels have been demonstrated to predict efficacy of platinum agents. Similarly, low ribonucleotide reductase M1 (RRM1) predicts efficacy of gemcitabine , and elevated SPARC  predicts sensitivity to nab -paclitaxel. Polymorphisms of topoisomerase 
I (TOP1) have been implicated in irinotecan resistance in lung and colorectal cancer.
3,4,5,6 hENT1 is a 
major transporter of gemcitabine and low levels are associated with gemcitabine  resistance.  In addition 
SMAD4 expression has been identified as a predictor of local versus distant disease progression in pancreatic cancers.
7,8 
June 28 2018, Amendment 18 15 1.2. Proposed Therapeutic Intervention 
 This protocol uses sta te-of-the- art immunohistochemistry (IHC) to determine if molecular targets are 
present in a patient’s tumor. Then, chemotherapeutic regimens will be individualized and optimized for 
each patient’s tumor, based on the molecular characterization of these tar gets. Success of the approach 
will be measured by [CONTACT_751190], overall survival and progression -free survival for the 
study patients to historical data (i.e. gemcitabine or capecitabine-based chemo radiation for resectable 
patients and co mbined modality therapy for borderline resectable patients).2,9 Prior to chemotherapy, 
radiation or surgery, the patient will consent to providing a specimen by (Endoscopic Ultrasound Fine Needle Aspi[INVESTIGATOR_1516]) EUS/FNA or traditional biopsy for molecular p rofiling to determine the neoadjuvant 
therapy agent(s) of choice. Postope ratively the surgical specimen will  also be profiled to guide any 
potential adjuvant regimen . We have previously shown proof of concept in our feasibility study entitled 
Molecular Pro filing of Endoscopic Ultrasound Fine Need Aspi[INVESTIGATOR_751168]: A 
Feasibility Stu dy.
10 
2. OBJECTIVES AND STUDY DESIGN  
2.1. Objectives 
2.1.1. Primary Objective  
 The primary objective is to compare the resectability rate (percent of all patients completing therapy 
to include surgical resection ) using a neoadjuvant treatment regimen selected by [CONTACT_751191] . 
2.1.2. Secondary Objectives (objectives noted by [CONTACT_61140] (*) will be pursued only at the coordinating 
site) 
1. To compare overall survival (OS) rates of resectable and borderline resectable pancreatic cancer 
patients treated with molecularly targeted neoadjuvant therapy followed by [CONTACT_751192] . 
2. To compare progression- free survival (PFS) rates of patients with resectable  and borderline resectable 
pancreatic cancer treated with molecularly targeted neoadjuvant therapy followed by  [CONTACT_751193] . 
3. To determine the frequency with which  molecular profiling of a patient’s tumor by [CONTACT_751186] a 
target for an approved, commercially -available chemotherapeutic regimen . 
June 28 2018, Amendment 18 16 4. To compare the molecular profile of pretreatment biopsies and resected tumors. We will compare the 
molecular profile obta ined at time of diagnosis (FNA ) with the molecular profile obtained from the 
resected specimen.  
5. To determine the extent of histologic treatment response to targeted chemotherapeutic regimens in resected tumors. * 
6. To determine the prognostic relevance of radiological response among patients undergoing neoadjuvant therapy. 
7. To determine the ability to generate primary xenografts of pancreatic cancer from resected tumors. * 
8. To compare quality and outcomes of both patterns of recurrence and ultimat ely survival in patients 
who receive radiation therapy at FH/MCW versus other institutions.   
 
2.2. Study Design 
 This is an open-label, multi -institution , phase II study in patients with resectable and borderline 
resectable pancreas cancer . MCW will be the coordinating site and University  of Cincinnati will be a 
participating site. Patients will be staged with laboratory tests, contrast -enhanced computed to mography 
(CT) and magnetic resonance imaging (MRI) of the abdomen, a chest radiograph or contrast enhanced  
chest CT, and PET scan . MRI’s and PET scans are at the physician’s discretion.  At initial staging,  each 
patient will be classified resectable or borderline resectable based on review of all CT or MRI images (see 
section s 3.1.1 and 3.1.2 for definitions) .  
 A patient is eligible for screening for this study when his/her disease is designated highly suspi[INVESTIGATOR_751169].  After signing the screening consent form, patients will undergo EUS/FNA or 
have a tumor biopsy from a prior FNA or laparotomy/ lapar oscopy available for molecular profiling. 
When FNA (or previous biopsy) histology confirms pancreatic adenocarcinoma, the patient is eligible to 
participate in the study and will sign the enrollment consent form . Molecular profiling will be performed 
on tumor biopsies from approximately [ADDRESS_1028358] patients will be enrolled at 
the coordina ting site.  IHC will be performed to assess specific molecular targets on tumor biopsies. It is 
expected that molecular targets will be identified in approximately 70% of tumor biopsies (i.e. 120 patients) . Study patients will be treated neoadjuvantly with commercially available systemic therapy 
assigned on the basis of disease stage (resectable or borderline resectable)  and identified molecular 
targets. No investigational treatments will be administered .  Study patients who have no molecular tar gets 
identified on pre- treatment FNA/biopsy will be treated with neoadjuvant therapy according to current best 
standard of care.
2,9 
June 28 2018, Amendment 18 17  Patients whose disease is stable or responding by [CONTACT_751194], clinical, and radiographic measures 
will be offered resection.  P atients whose disease demonstrates progression but are still considered 
technically operable may receive additional therapy prior to resection (see figure s A page 48  and B page 
49). Patients whose disease demonstrates progression beyond operability will be taken off study. 
Treatment response will be evaluated in a multi-disciplinary setting and assessment of operability will be 
made at the discretion of the treating surgeon and include the following components: (1) feasibility of 
surgical resection, (2) decline in Ca19-9 levels (in patients  for who m Ca19 -9 is evaluable) , and (3) 
acceptable performance status.  
 All study patients who proceed to surgery will undergo laparoscopy at the time of surgery to assess 
for occult metastases. Surgical resection  will be performed using a standard technique11 and patients will 
be followed for major surgical complications . Resectability rate , which measures the study’s primary 
objective, is the proportion of patients who undergo a successful PD as compared to all patients who 
initiate neoadjuvant therapy.  
 Standardized histologic evaluation of the resected specimen will be performed . Histologic response to 
preoperative therapy will be graded (see Appendix B).12Molecular profiling will also be performed on the 
surgical specimen . Study patients will be restaged and will be given up to 4 months adjuvant therapy on 
study with restaging after each 2 months of therapy. If, at any point during restaging, the patient’s disease 
has recurred,  he/she will come off treatme nt and remain in follow-up for survival. 
 Study patients whose cancer does not recur after adjuvant therapy will be followed with serial CT 
scan and laboratory tests at 3 month intervals  (plus or minus a 1 month window) to assess for disease 
recurrence and survival for the first 18 months  following end of treatment  and then at 6 month intervals  
thereafter  until 5 years from date on study. Patients whose disease recurs during follow-up will remain in 
follow-up for survival only .  If patients develop metastatic disease that is amenable to mi nimally invasive 
biopsy or resection, surgery may be considered to obtain tissue for further molecular characterization .
 Sample size for screening is estimated at 288 .  Sample size for treatment will be 168 patients accrued 
over 4 years of which only 130patients will actually begin treatment. Details on sample size and power are included in Statistical Methods, Section 11. 
      Essential data will be collected while the patient is on study in order to evaluate the study objectives. This data will be collected directly from the patient’s medical record and/or from the HPB Clinical 
Database.   Relevant safety data concerning adverse events will also be collected. Whenever possible, 
initial staging and all restaging will be completed at the study site. Surger y must be performed by [CONTACT_751195] 28 2018, Amendment 18 18 site’s pancreatic cancer team. All nonsurgical therapi[INVESTIGATOR_751170]’s local oncologists.    
 Several translational correlates are incorporated into the study design to further characterize the 
primary tumor genotype as well as to evaluate the accumulation of genetic alterations associated with the 
development of metastatic disease. After pathologic evaluation is complete, resected specimens of both primary and metastatic lesions will undergo repeat molecular profiling  to evaluate for changes in 
molecular phenotype. To prepare the resected tumor for further molecular characterization, resected tumors will be expanded using a direct xenograft model.  
 2.2.1. T reatment S trategy 
 The treatment delivered to each patient will be first determined by [CONTACT_751196] (resectable 
vs. borderline resectable - see 3.1.1 and 3.1.2 for definitions) as summarized by [CONTACT_105287] A:  page 48 
(resectable) and Figure B:   page 49 (borderline resectable).   All patients will undergo EUS/FNA biopsy 
and, based on the out come of the molecular profiling analysis of the biopsy, treatment wil l be assigned as 
summarized in Figure C. In particular, tumor specimens will be evaluated for expression of RRM1, 
ENT1, TYMS, TOP1, ERCC1, SPARC  and SMAD4 . The staining pattern of the STREET panel will be 
reviewed in a multi -disciplinary conference at the coordinating site and a final treatment plan determined.  
The treatment plan will be communicated to the Principal Investigator [INVESTIGATOR_022]/her designee at the 
participating site  and to treating physicians. (see Letter Format s, Appendix M) 
Research may take place in an inpatient or outpatient setting. The research -only procedures 
include the extra FNA passes, molecular profiling, and collection of blood at several time points 
throughout the study. Molecular profiling will be conducted only at the coordinating site, 
FH/MCW.   Extra FNA passes and collection of blood at several time points throughout the study will be 
conducted at the enrolling site (FH/MCW or Univers ity of Cincinnati).  Specimen collection will be 
conducted by [CONTACT_751197].   
Procedures that this research encompasses but are standard of care (i maging including MRI, PET 
scan, Chest X -ray and CT Scans;   Endosopic Ultrasound-guided Fine Needle Aspi[INVESTIGATOR_1516] (EUS FNA; 
blood tests, medical team consultations, pregnancy test prior to chemotherapy and prior to surgery, chemotherapy, chemo- radiation therapy) may take place at FH/MCW  or at  another cancer treatment 
location. Surgery (pancreatico -duodenectomy) will be standard cancer care treatment and  take place at the 
patient’s enrolling site (FH/MCW or University of Cincinnati).  
  
June 28 2018, Amendment 18 19 Those administering treatment will be deemed qualified to administer per Froedtert policy and/or 
MCW policy.  
 
 
 
 
  
 
 
 
[REMAINDER OF PAGE INTENTIONALLY BLANK]  
 
  
 
   
 
   
 
   
June 28 2018, Amendment 18 20 TABLE 1:  
THRESHOLD VALUES USED FOR IMMUNOCHEMISTRY INTERPRETATION                    
Biomarker  Intensity    Percent Stain  Interpretation  ACTION  
RRM1  >=2+  AND  >=50%  HIGH  No Gem  
RRM1  >=2+  AND  <50%  MODERATE  Gem  
RRM1  <2   ? LOW  Gem  
RRM1  0     NEGATIVE  Gem  
ENT1  >=2 AND  >=25%  POSITIVE  Gem  
ENT1  <2 OR <25%  LOW  Gem  
ENT1  0     NEGATIVE  No Gem  
TYMS  >=2 AND  >=30%  HIGH  No 5 -FU 
TYMS  >=2 AND  <30%  MODERATE  5-FU 
TYMS  1+ AND  >=25%  MODERATE  5-FU 
TYMS  1+ AND  <=25%  LOW  5-FU 
TYMS  0     NEGATIVE  5-FU 
TOP1  >=2 AND  >=30%  HIGH  Irinotecan  
TOP1  <2 OR <30%  LOW  No Irinotecan  
TOP1  0     NEGATIVE  No Irinotecan  
ERCC1  3   HIGH  No Plat  
ERCC1  2 AND  >50%  HIGH  No Plat  
ERCC1  2 AND  <50%  LOW  Platinum  
ERCC1  0-1   LOW  Platinum  
June 28 2018, Amendment 18 21 SPARC  >=2+  OR >=30%  HIGH  nab 
SPARC  <2+ AND  <30%  LOW  nab 
SPARC  [ADDRESS_1028359] be initiated within 0 -4 
weeks after the enrollment consent is signed.  
  A djuvant therapy will be administered as summarized in either Figure D (page 51 ) or  
Figure E ( page 52 ).  Adjuvant therapy must be initiated within [ADDRESS_1028360] 
available therapi[INVESTIGATOR_014].   The recommended treatment will take into account input from the medical oncolog y 
investigators, patient performance status, co- morbidities, and contraindications. When necessary, other 
relevant factors concerning the patient’s clinical history and current medical literature will also be taken into consideration. The schema of biomarker  and corresponding agents in Figure s C (page Error! 
Bookmark not defined.), D ( page 51) and E ( page 52 ) will be periodically updated as methodologies and 
therapi[INVESTIGATOR_751171]. Each site will notify its respective IRB of changes made to th e 
treatment strategies . 
 Throughout treatment on this protocol, dose modifications , supportive care, and treatment of 
chemotherapy- related toxicity will  be made at the physician’s discretion following manufacturer’s 
guidelines (see Appendix F) and standard supportive care (Appendix L).  If insurance denies coverage for the standard treatment that has been identified per t he protocol, then another standard treatment will be 
identified by [CONTACT_751198] (see Figure C, D or E). 
2.2.2. [Neoadjuvant] Pre -operative Pathway for Resectable  Patients  
Patients with resectable pancreatic cancer will receive the following preoperative therapy:  (refer to Fig. 
A, p. 46) 
1. For resectable patients where molecular profiling is predictive:  
June 28 2018, Amendment 18 22 • 6-[ADDRESS_1028361] profile- directed therapy   
• Restaging  
• In the absence of disease progression - surgery  
2. For resectable patients whose specimen is adequate but molecular profiling is not predictive (profile 
not predictive) or for inadequate specimens ( target  not identified ): 
• Gemcitabine or Capecitabine- based chemo radiation  
• Restaging 
• In the absence of disease progression – surgery – which should occur 3- 6 weeks after  
   Chemotherapy completion       
 
2.2.3. [Neoadjuvant] Pre -operative Pathway for Borderline Resectable Patients  
 Patients with borderline resectable pancreatic cancer will receive the following preoperative therapy:  
(refer to Fig. B, page 47)  * If at any restaging , unequivocal distant disease progression is identified on 
imaging patients will be considered to have progressive disease and proceed to off study follow -up. 
1. For borderline resectable patients where molecular profiling is predictive:  
• 6-[ADDRESS_1028362] profile- directed systemic therapy    
• Restaging * 
• Chemo radiation   
• Restaging *   
• Surgery 
2. For borderline resectable patients whose molecular prof iling is successful, but a target is not 
predicted.  (profile not predictive) :  
• Gemcitabine or Capecitabine- based chemo radiation  
• Restaging * 
• Surgery  
3. For borderline resectable patients with inadequate specimens (target not identified) :  
• FOLFIRINOX (4 cycles)  
• Restaging * 
• Chemo radiation  
• Restaging * 
June 28 2018, Amendment 18 23 • Surgery which should occur 3- 6 weeks after chemotherapy completion  
2.2.4. [Neoadjuvant]  Preoperative Treatment  
[IP_ADDRESS] [Neoadjuvant] Preoperative FNA Profiling Schema  (Figure C  page Error! Bookmark not 
defined. ) 
[IP_ADDRESS]. [Neoadjuvant] Preoperative Treatment Regimens  
 NOTE:  all pre -operative regimens  (a-j) are identical  to post- operative regimens (a -j); and post -
operative regimens (k -n) are not pre-operative options. 
 When dose reductions are necessary, the treating physician will refer to current package 
inserts.   Dose reductions will be at the discretion of the treatin g physician who is expected to be in contact 
[CONTACT_9881].  
a. Gemcitabine -based XRT Treatment Regimen:  
Chemotherapy: Gemcitabine 400mg/m2 IV at fixed dose rate, infused over 40 minutes on Day 1 (day -2 to 
+1), and then weekly x 6 during radiation therapy. 
Radiation: External-beam radiation therapy will be delivered 5 days/week over 5.5 weeks with  6-18-
MeV photons . Using 3D conformal or IMRT techniques , patients will receive a total dose of 50.4 Gy 
prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).2  
b. Capecitabine -based XRT Treatment Regimen:  
Chemotherapy: Capecitabine 825 mg/m2 orally twice daily on Day 1 and continuing Monday through 
Friday during radiation. 
Radiation: External-beam radiation therapy will be delivered 5 days/week over 5.5 weeks with  6-18-
MeV photons. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy 
prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).13 
c. FOLFIRINOX Treatment Regimen:  
FOLFIRINOX:  On Day 1, oxaliplatin 85 mg/m2 IV infused over 120 minutes, irinotecan 180 mg/m2 IV 
infused over 90 minutes, leucovorin 400 mg/m2 IV infused over 120 minutes, followed by [CONTACT_751199] (5 -FU) 400 mg/m2 IV; followed by 5-FU 2,400 mg/m2 IV as a 46 -hour continuous infusion, 
cycled every 2 weeks for a total of 2 months of therapy.14  
d. FOLFIRI Treatment Regimen:  
FOLFIRI: On Day 1, Irinotecan 180 mg/m2 IV infused over 90 minutes, leucovorin 400 mg/m2 IV infused 
over 120 minutes, followed by [CONTACT_751200] (5- FU) 400 mg/m2 IV; then 5-FU 2,400 mg/m2 IV as a 
46-hour continuous infusion, cycled every 2 weeks for a total of 2 months of therapy. 
e. Gemcitabine w/irinotecan Treatment Regimen:  
June 28 2018, Amendment 18 24 Gemcitabine 1,000 mg/m2 IV infused over 30 -40 minutes followed immediately by [CONTACT_372338] 100 mg/m2 
IV infused over 90 minutes, both administered on Days 1 and 8 and cycled every 3 weeks for a total of 2 
cycles. 16 
f. Gemcitabine w/ oxaliplatin Treatment Regimen:  
Gemcitabine 1,0 00 mg/m2 IV infused over 30 -40 minutes on Day 1 and a 2-hour infusion of oxaliplatin 
100mg/m2 IV on day 2, cycled every two weeks for a total of 3 cycles.17 
g. Gemcitabine w/ cisplatin Treatment Regimen:  
Gemcitabine 750 mg/m2 IV infused over 30-40 minutes and cisplatin 30 mg/m2 IV infused over 30 
minutes, cycled every 2 weeks for 3 cycles.18 
h. Gemcitabine/capecitabine Treatment Regimen:  
Gemcitabine 1000 mg/m2 IV infused over 30 -40 minutes Days 1, 8 and 15 and capecitabine 825 mg/m2 
orally twice daily on days 1- 21 cycled every 4 weeks for a total of 2 cycles.19 
i. Gemcitabine/nab -paclitaxel Treatment Regimen:  
Nab-paclitaxel 125 mg/m2 IV infused over 30 -40 minutes (maximum infusion time not to exceed 40 
minutes) followed by [CONTACT_35421] 1000mg/m2 IV infused over 30 -40 minutes on Days 1, 8, and 15, 
cycled every 28 days for a total of 2 cycles.21 
j. Capecitabine/nab- paclitaxel Treatment Regimen:  
Nab-paclitaxel 125 mg/m2 IV on day 1, 8 ) and capecitabine 825 mg/m2 PO BID days 1- 14 on a Q3 week 
cycle.  Repeat for 3 cycles.22 
[IP_ADDRESS]. Disease Progression on Therapy  
 If the patient has resectable  disease that progressed locally, but remains resectable  and had: 
   1.   Induction chemotherapy, then the patient may be given chemoXRT based on 
multidisciplinary review.  Restaging will be performed  upon completion of therapy to assess 
resectability.  
   2.   ChemoXRT, then proceed to surgery. 
 3.   ChemoXRT with development of indeterminate liver or lung lesions and/or rising     
             CA19 -9:  Add an additional 2 months of chemotherapy per PI [INVESTIGATOR_9106]. 
              Restaging will be performed upon completion of therapy to assess resectability.  
 If the patient had borderline resectable disease that progressed to locally advanced: 
June [ADDRESS_1028363] patient on survival follow up. 
 If the patient has unequivocal metastatic disease on imaging studies:  
   1.   The patient will be considered inoperable, removed from treatment , and followed for 
survival. 
2.2.5. [Adjuva nt] Pathways for all patients  after Postoperative Restaging  
1. No evidence of disease, target is identified in surgical specimen, and molecular profiling is 
predictive:  
If neoadjuvant ChemoXRT has not  been given: 2-[ADDRESS_1028364] profile-directed therapy ( See Figure D 
page 51). 
If neoadjuvant ChemoXRT has been given: [ADDRESS_1028365] profile- directed therapy.    (See Figure E 
page 52 ). 
 2. No evidence of disease: target is not  identified in the surgical specimen or target is identified in 
the surgical specimen and molecular profiling is not  predictive:  
If neoadjuvant ChemoXRT has not  been given:  
 2 months of Chemo/XRT or  
 [ADDRESS_1028366] chemotherapy  (See Figure D page 51 ). 
If neoadjuvant ChemoXRT has been given:  
4 months of systemic therapy – target not identified or SMAD4 loss  or 
 No further therapy – SMAD4 intact  (See Figure E page 52). 
 3. Evidence of disease recurrence or metastasis:  
Off-treatment, and moved to follow-up (see Section 6.5 for Follow-up). 
2.2.6. [Adjuvant] Postope rative Treatment    
[IP_ADDRESS]  [Adjuvant] Postoperative Profil ing Schema no prior XRT (Figure D page 51) 
[IP_ADDRESS]  [Adjuvant] Postoperative Profiling Schema when patient DID receive pre- operative XRT  
(Figure E  page 52 ) 
[IP_ADDRESS].  [Adjuvant] Postoperative Treatment Regimens 
 NOTE:  all post -operative regimens (a -j) are identical to pre- operative regimens (a-j); and post-
operative regimens ( k-n) are not pre-operative options: 
a. Gemcitabine- based XRT Treatment Regimen:  
June 28 2018, Amendment 18 26 Chemotherapy: Gemcitabine 400mg/m2 IV at fixed dose rate, infused over 40 minutes on Day 1 (day -2 to 
+1), and then weekly x 6 during radiation therapy. 
Radiation: External-beam radiation therapy will be delivered 5 days/week over 5.5 weeks with  6-18-
MeV photons. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy 
prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).2  
b. Capecitabine -based  XRT Treatment Regimen:  
Chemotherapy: Capecitabine 825 mg/m2 orally twice daily on Day 1 and continuing Monday through 
Friday during radiation. 
Radiation: External-beam radiation therapy will be delivered 5 days/week over 5.5 weeks with  6-18-
MeV photons. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy 
prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions). 13 
c. FOLFIRINOX Treatment Regimen:  
FOLFIRINOX:  On Day 1, oxaliplatin 85 mg/m2 IV infused over 120 minutes, irinotecan 180 mg/m2 IV 
infused over 90 minutes, leucovorin 400 mg/m2 IV infused over 120 minutes, followed by [CONTACT_751199] (5 -FU) 400 mg/m2 IV; followed by 5-FU 2,400 mg/m2 IV as a 46 -hour continuous infusion, 
cycled every 2 weeks for a tot al of 2 months of therapy.14  
d. FOLFIRI Treatment Regimen:  
FOLFIRI: On Day 1, Irinotecan 180 mg/m2 IV infused over 90 minutes, leucovorin 400 mg/m2 IV infused 
over 120 minutes, followed by [CONTACT_751200] (5- FU) 400 mg/m2 IV; then 5-FU 2,400 mg/m2 IV a s a 
46-hour continuous infusion, cycled every 2 weeks for a total of 2 months of therapy.20 
e. Gemcitabine w/ irinotecan Treatment Regimen:  
Gemcitabine 1,000 mg/m2 IV infused over 30 -40 minutes followed immediately by [CONTACT_372338] 100 mg/m2 
IV infused over 90 minutes, both administered on Days 1 and 8 and cycled every 3 weeks for a total of 2 cycles.  
16    
f.. Gemcitabine w/ oxaliplatin Treatment Regimen:  
Gemcitabine 1,000 mg/m2 IV infused over 30 -40 minutes on Day 1 and a 2-hour infusion of oxaliplatin 
100mg/m2 IV on day 2, cycled every two weeks for a total of 3 cycles. 17  
g. Gemcitabine w/ cisplatin Treatment Regimen:  
Gemcitabine 750 mg/m2 IV infused over 30-40 minutes and ci splatin 30 mg/m2 IV infused over 30 
minutes, cycled every 2 weeks for 3 cycles.  18  
h. Gemcitabine/capecitabine Treatment Regimen:  
June 28 2018, Amendment 18 27 Gemcitabine 1000 mg/m2 IV infused over 30 -40 minutes Days 1, 8 and 15 and capecitabine 825 mg/m2 
orally twice daily on days 1- 21, cycled every 4 weeks for a total of   2 cycles.   19 
i. Gemcitabine/nab -paclitaxel Treatment Regimen:  
Nab-paclitaxel 125 mg/m2 IV infused over 30 -40 minutes (maximum infusion time not to exceed 40 
minutes) followed by [CONTACT_35421] 1000mg/m2 IV infused over 30 -40 minutes on Days 1, 8, and 15, 
cycled every 28 days for a total of 2 cycles . 21 
j.  Capecitabine/nab -paclitaxel Treatment Regimen: 
Nab-paclitaxel 125 mg/m2 IV on day 1, 8  and  
capecitabine 825 mg/m2 PO BID days 1-14 on a Q3 week cycle.  Repeat for 3 cycles.22 
k. Gemcitabine alone Treatment Regimen:  
Gemcitabine 1000 mg/m2 IV infused over 30 -40 minutes, cycled every week times 3 weeks; 1 week off 
and then 3 more weeks for a total of 6 cycles. 23 
l. Capecitabine alone Treatment Regimen:   
Oral capecitabine 1,250 mg/m(2) administered twice daily (2,500 mg/m(2)/d) in 3 -week cycles consisting 
of 2 weeks of treatment followed by 1 week without treatment. 24 
m. 5FU alone Regimen:   
Give per physician discretion standard of care. 15,24 
n. No further treatment recommended :  
 Molecular profiling suggest s that no further target s are identified.  
2.2.7. Outcome Measures  
 Disease status will be assessed at each restaging evaluation (clinical parameters, CT and/or MRI 
imaging, tumor markers) . If progression is not observed at the end of study therapy, patients will be 
assessed ever y 3 months (plus or minus a 1 month window)  for the first  18 months after study therapy has 
ended and then every 6 months until 5 years after enrollment/registration . PFS and OS will be reported.   
Adverse events will be monitored  and collected in a summary format summary format as delineated in the 
study calendar (sections 6.6 and 6.7). See Sections 8.1 and 8.2 for adverse event reporting details.  
 
  
June 28 2018, Amendment 18 28 3. PATIENT SELECTION  
3.1. Screening  and Eligibility Criteria 
To be eligible  to sign a screening consent  (see Appendix I : Eligibility Checklist ) patients must : 
• Have adenocarcinoma of the pancreas or highly suspi[INVESTIGATOR_751172]  
• 18 years of age or older 
• Able to understand and provide written informed consent or have Legally Authorized 
Representative (LAR)  
To be eligible to sign enrollment consent, the patient must have a confirmed diagnosis of pancreatic 
adenocarcinoma. After enrollment consent is signed, treatment eligibility is confirmed. If treatment 
eligibility is not met, the patient will be treated off study and will not be followed on study. 
3.1.1. Treatment Eligibility Criteria:  
• Enrollment consent must have be en signed. 
• Have an ECOG performance status < 2  
• Have b iopsy-proven, resectable (defined in Section 3.1.2) or borderline resectable  (defined in 
Section 3.1.3) adenocarcinoma of the p ancreas based on CT or MRI findings as detailed in Sections 
3.1.[ADDRESS_1028367] be / have been  completed within 2 months prior to molecular 
profiling. 
• Have adequate organ and bone marrow function as defined by:   
o  total leukocytes >3 x103/μL 
o  absolute neutrophil count (ANC) >1.5x 103/μL 
o  hemoglobin >9 g/dL  
o  platelets >100 x 10e3/μL  
o  creatinine clearance > 60 mL/min or creatinine <1.5 mg/dL  
o  bilirubin < 2 mg/dL :  At two weeks from biliary decompression, if the subject’s serum 
bilirubin  remains greater than two, but has demonstrated a progressive decline, the subj ect 
may be enrolled i nto the trial  and appropriate modification and dose adjustments will be 
made to the predicted regimen. Eligibility of  subjects whose bilirubin levels remain elevated 
above 2, without demonstrating a downward trend, will be determined at the discretion of the 
trial PI s and their treatment assignment . 
o  aspartate transaminases (AST/SGOT)   <[ADDRESS_1028368]  
o  alanine trans aminases (ALT/SGPT)  <[ADDRESS_1028369] 
June 28 2018, Amendment 18 29 •  Female patients must be post -menopausal for > [ADDRESS_1028370] dose of any study drug.  
3.1.2.Definition of Resectable Pancreatic Can cer includes  all of the following:  
• No evidence of extra pancreatic disease  
• No evidence of tumor -arterial abutment (celiac, SMA  [superior mesenteric artery]  or HA [hepatic 
artery] ) 
• If tumor induced narrowing of the SMV [superior mesenteric vein], PV [portal vein] or SMV- PV 
[superior mesenteric -portal vein] confluence is present, it must be <50% of the diameter of the 
vessel  
•   Ca 19 -9 <5000, when bilirubin is <[ADDRESS_1028371] one of the following:  
• Tumor abutment <180° of the SMA or celiac axis  
• Tumor abutment or encasement of a short segment of the HA  
•  Tumor induced narrowing of SMV, PV or SMV- PV of > 50% of the diameter of the vessel.  
• Short segment occlusion of the SMV, PV or SMV-PV with a suitable PV above and SMV below, for reconstruction  
• CT or MRI findings suspi[INVESTIGATOR_271] , but not diagnostic of, metastatic disease (based  on review at each 
site’s weekly  multidisciplinary  pancreatic cancer conference)  
• Biopsy proven N1 disease (regional lymph nodes involved) from pre- referral biopsy or EUS-guided 
FNA 
• Resectable tumor and CA 19 -9 >5000 
3.1.4. Definition of Locally Advanced   
• Artery:  Tumor encasement (> 180°) of SMA or celiac artery  
• Vein  Occlusion of SMV, PV or SMV- PV without suitable vessels above and below the tumor to 
allow for reconstruction (no distal or proximal target for vascular reconstruction) 
June 28 2018, Amendment 18 30 • Extra pancreatic di sease:  No evidence of peritoneal , hepatic , or extra-abdominal metastases  
3.1.5. Definition of Metastatic Disease  
• Evidence of peritoneal or dist ant metastases  
3.2. Exclusion Criteria 
 Any patient with one or more of the following will be excluded:  
• Have r eceived chemotherapy or  chemoradiation within  5 years prior to study enrollment 
• Have any previous history of another malignancy (other than cured basal  or squamous cell  
carcinoma of the skin or cured in-situ carcinoma of the cervix) within 5 years of study en rollment 
• Uncontrolled co morbidities  including, but not limited to, ongoing or active serious infection, 
symptomatic congestive heart failure, unstable angina, unstable cardiac arrhythmias, psychiatric 
illness, excessive obesity, or situations that would limit compliance with the study requi rements or 
the ability to willingly give written informed consent 
• Known HIV, HBV, or HCV infection  
• Pregnant or breast- feeding patients or any patient with child- bearing potential not using 
contraception [ADDRESS_1028372] atic disease may 
choose to participate in additional translational correlative studies and will be asked to sign a separate 
consent for tissue procurement and molecular analysis. 
5. SCREENING AND ENROLLMENT  
 Investiga tors or their appropriate designees will i dentify potentially eligible patients from their 
clinics, patient self -referrals, or referrals from other clinicians . Inclusion/exclusion criteria will be 
reviewed and patient eligibility will be confirmed after both screening and enrollment consents are signed 
and screening is complete.   Globally, i t is expected that approximate 288 patients will sign screening 
consents; [ADDRESS_1028373] 38patients to exclude before treatment starts and 130  will start study treatment globally . Of these global patients,  up to 10 patients will 
sign screening consents and up to 6 will sign enrollment consents at our participating site , the University 
of Cincinnati .  Of those it is expected that up to 4-6 will start treatment  at the University of Cincinnati. 
June 28 2018, Amendment 18 31  If the patient  (or LAR, legally authorized representative)  agrees to study participation, first, he/she 
must provide signed informed consent for study screening .  After signing a screening consent form, each 
patient will be assigned a unique subject number. The investigator will then request a biopsy (EUS/FNA 
preferred) to obtain a tumor sample for the study if not already available . The tumor biopsy must be 
performed within [ADDRESS_1028374] any intervening anticancer 
treatment between the time of the biopsy and the IHC and microarray analysis. 
 When histology from the tumor biopsy confirms pancreatic adenocarcinoma, the pati ent will sign the 
enrollment consent and be evaluated for all inclusion /exclusion criteria . If all criteria are met, the subject 
will undergo study treatment.   Neoadjuvant treatment must be initiated [ADDRESS_1028375] specimens that  are inadequate for molecular characterization , 
mayundergo an EUS/FNA biopsy. During EUS/FNA, extra passes will be obtained for processing into 
cell blocks that will be utilized for molecular profiling.   The study laboratory m anual describes the methodology to be followed by [CONTACT_66923][INVESTIGATOR_751173]. See Laboratory Manual: Section 2:  Fine Needle Aspi[INVESTIGATOR_751174] 
(Appendix J). The endoscopi[INVESTIGATOR_751175].  
6.2. Methodology for Processing FNA Specimen and Shippi[INVESTIGATOR_751176]. Slides will also be made at 
either the participating site or the coordinating site . The participating site will ship cell block s and, if 
available, slides to the coordinating site . The study laboratory manual describes the methodology to be 
followed for processing FNA specimens and shippi[INVESTIGATOR_007]. See Laboratory Manual  (Appendix J). Laboratory 
procedures may be revised as required to maximize processing quality.  
6.3. Characterization of Specimen 
6.3.1. Overview  
 After a diagnosis of pancreatic adenocarcinoma has been histologically confirmed, the remaining cell 
block will be used to perform further characterization of the tumor using IHC for the targets of interest.    
June 28 2018, Amendment 18 32 6.3.2. Immunohistochemistry  
 Immunohistochemical staining for MASPIN, S100P, RRM1, ENT1, TYMS, TOP1 , ERCC1, SPARC, 
and SMAD4  will be performed using the available cell block .  The antibodies will be purchased from 
commercially available sources an d the staining procedure has been optimized on retrospective cell 
blocks. IHC evaluation  will be made using appropriate positive and negative controls .  (See Table 1  (page 
20)  for interpretation of staining intensity and percent stain).26  
6.3.3. Molecular Analysis  
 If adequate specimen is available, RNA and/ or DNA will be extracted from the available cell blocks.  
Gene expression will be done on the following genes:   RRM1, ENT1, TYMS, TOP1, ERCC1, and 
SPARC . Expression levels will be normalized to GUSB whic h is a housekeepi[INVESTIGATOR_751177].  Mutational analysis is done using a single pool of primers to perform multiplex PCR for 
preparation of amplicon libraries from genomic "hot spot" regions and/or all-exon coverage of genes that 
are frequently mutated in hu man cancer genes. (See the study Lab Manual for a representative list of these 
genes). 
6.3.[ADDRESS_1028376] panel will be reviewed in a multi-disciplinary confere nce at 
the coordinating site and a final treatment plan determined.  The treatment plan will be communicated to 
the Principal Investigator [INVESTIGATOR_022]/her designee at the participating site and to treating physicians. 
6.3.[ADDRESS_1028377] been able to receive the nonsurgical components of 
their treatment either here at Froedtert and the FMLH/MCW affiliates or at outside institutions.  There 
is interest in reviewing all of the radiation therapy data for quality, including adherence to the protocol 
radiation dose/volume guidelines as well as reviewing contouring of targets and organs at risk, dose 
volume histograms, and dose distributions, and correlating this with outcome.  There is data from 
nationa l cooperative postoperative radiation trials, used for the treatment of pancreatic cancer, which 
reveal the difference in local control and survival that adherence to protocol parameters and radiation quality can make.  We would like the opportunity to ext end this review to this protocol  and specifically 
focus on the quality of the radiation delivered both here at FMLH/MCW and outside of our institution.  This will entail obtaining all of the radiation treatment planning records from the participants in the  
study with review of the contours, dose distribution, dose volume histograms, and patterns of 
recurrence to  support the impact on local control and survival that the quality of the radiation delivered 
in the neoadjuvant and adjuvant setting can make.  
6.4. Study Assessments 
 Patients will be evaluated as outlined in the study schema (see Sections 6.6 and 6.7).  
1.    Prior to neoadjuvant therapy 
June 28 2018, Amendment 18 33 2.   After 2  months of neoadjuvant therapy if 4 months of neoadjuvant therapy are planned     
(responding or stable disease)  
3.    Prior to surgery with assessment of disease status (responding or stable disease)  or progressing 
but still operable.  
4.    1-3 months after surgery /  prior to adjuvant treatment with assessment of disease status.  
5.    Afte r 2 months of adjuvant therapy if 4 months of adjuvant therapy are planned.  
6.    After final study therapy is complete with assessment of disease status.  
7.    Hematology will include CBC with differential including platelet count and hemoglobin. 
Biochemistry will include ALT/SGPT, AST/SGOT, total b ilirubin, and GFR or creatinine.  
Tumor markers will include Ca 19 -9 (for patients who express Ca 19 -9), and CEA. 
6.5. Follow-up  
 If a subject discontinues for any reason, molecular profile results will be given to the subject’s 
physician to  consider alternative therapi[INVESTIGATOR_014].  
• Patients with inoperable disease progression  will come off treatment  and be followed for survival 
every 6 months. 
• For patients without inoperable disease progression at the end of therapy, tumor assessments are to 
be undertaken every 3 months (plus or minus a 1 month window) for the first 18 months, then every 
6 months for  years until 5 years from enrollment on study.  
 
 
November 24, 2015, Amendment 13   34 
 
 Visit Number: 1 2 3 4 5 6 ~7 ~8 ~9 ~10 11-17+ NA
Visit Name:
[INVESTIGATOR_499893]                   0-
3 weeks
Enroll / Stage      
0-4 wks
Chemo or ChemoXRT    
5-12 weeks
#1          Restage       
0-6 weeks
Surgery           one 
day             
#2          Restage       
4-12 weeks
Chemo                           
5-12 weeks
#3          Restage      
0-6 weeks
Chemo or ChemoXRT    
5-12 weeks
#4          Restage        
0-6 weeks
On Study      FU q 
12 weeks x 6,  
then q 6 mos
Survivial FU       q  
6 mos
X
X X
X X X X X X
(X) (X) (X) (X) (X) (X)  
X
X X X X X
X
X X
Multidisciplinary 
Review  X X X X X X
Demographics
Medical History 
Phys Exam X X X X 
Tumor markers Ca 19-9, CEA X X X X
Hematology X X X X
BiochemistryX X X X
Pregnancy test - as per standard  † X† X† X†
ECOG Performance Status  !! !!  X X X X X
X
Confirm weekly that scheduled treatment is on track  (patients being treated outside MCW system only) X X X X X X X X
Survival assessment X X
◘     M RI abd/pelv is using a 3.0 Tesla see Section 7.2.3.       P ET &  M RI at Baseline &  for   RESEC TABLE at r estage 1;  for   BORDERLINE at r estage 1 and/or   r estage  2.
     When it is determined a patient's disease has progressed, the patient will move to off-study follow-up.
*       Pre-study tests and examinations are required within 6 weeks prior to treatment onset unless otherwise specified.
!!       ECOG must be < 2 at onset of initial tr eatment;                                                                 EC OG abov e 2 after  onset of initial tr eatment is captur ed in AE assessment.
    Physical Exam to include: vital signs, weight, review of systems, symptom assessment, and should be completed at least once from one staging to the next.
  Bilirubin must be < 2 when measuring Ca19-9. Only necessary for patient who express the CA19-9.~       RESEC TABLE patients On Study  will par ticipate in Visits 1, 2, 3, 4, 5, 6 &  11-17+.            Visits 7, 8, 9 &  [ADDRESS_1028378] prior to onset of tx Inclusion ChecklistdALT/SGPT, AST/SGOT, AlkP,  total 
bilirubin , GFR or creatinineX 
X† X 
X *Standard           
Care                  
ActivitiesMost 
RecentCBC with differential including 
platelet count and hemoglobin X Staging determined; when applicable, protocol-directed 
standard care tx recommendations provided to treating MD
 X 
X 
X  ◘Imaging:  PET & MRI  (per MD discretion)  (standard care activity)
STREET Profiling of tissue6.6 Schedule of Visits, Procedures and 
Laboratory Tests 
Resectable Arm Schedule of Events
SCREENING CONSENT
X Adverse event assessment    
Imaging:      CT abd & pelvis    with    Chest CT or Chest Xray (standard care activENROLLMENT CONSENT sign after  bx confims diagnosis;  pt may still e xclude  laX biopsy must not be older than [ADDRESS_1028379] prior to start of therapy                                    
(x) = may collect at OR and/or at any restageAT Coordinating SITE ONLY                 
Blood for research                         
June 28 2018, Amendment 18 35  Visit Number: 1 2 3 ~ 4 ~ 5 6 7 8 9~ 10~ 11~ 12~ 13-19+ NA
Visit Name:
[INVESTIGATOR_499893]                   0-
3 weeks
Enroll / Stage             
0-4 weeks
Chemotherapy          
8-12 weeks
#1          Restage       
0-2 weeks
Chemo XRT        5-
7 weeks
#2          Restage      
3-6 weeks
Surgery           one 
day             
#3          Restage       
4-12 weeks
Chemotherapy         
8-12 weeks
#4          Restage      
0-2 weeks
Chemotherapy        
8-12 weeks
#5          Restage        
0-2 weeks
On Study      FU q 
12 weeks x 6,  
then  q  6 mos
Survival     FU   q  
6 mos
X
X X
Adverse event assessment  X X X X X X X
(X) (X) (X) (X) (X) (X) (X)
X
X X X X X X
X X
X X
Multidisciplinary 
Review  X X X X X X X
Demographics
Medical History 
Phys Exam X X X X X
Tumor markers Ca 19-9, CEA X X X X X
Hematology X X X X X
BiochemistryX X X X X
Pregnancy test - as per standard † X† X† X† X†
ECOG Performance Status !!  X X X X X X
X
Confirm weekly scheduled treatment is on track (patients beingtreated outside MCW system on X X X X X X X X X X  
Survival assessment X X
 Bilirubin must be <  2 when measuring Ca19-9. Only necessary for patients who express the CA19-9.ENROLLMENT CONSENT  sign  after  bx  confir med diagnosis;  pt may  still ex clude l
Imaging:      CT abd & pelvis    with    Chest CT or Chest Xray (standard care activ
 Physical Exam to include: vital signs, weight, review of systems, symptom assessment, and should be completed at least once from one staging to the next.~       BORDERLINE patients On Study will participate in Visits 1, 2, 5, 6, 7, 8, 13-19+.     Visits 3,4,9,10,11,& 12 may or may not occur depending on the molecular profile. 
 ◘     MRI abd/pel vi s usi ng a 3.0 Tesl a see Secti on 7.2.3.       PET & MRI at Basel i ne & for  RESECTABLE at restage 1; for  BORDERLINE at restage 1 and/or  restage  2.
 When it is determined a patient's disease has progressed, the patient will move to off-study follow-up.
*       Pre-study tests and examinations are required within 4 weeks prior to treatment onset unless otherwise specified.
!!       ECOG must be < 2 at onset of initial treatment;                                                                ECOG above [ADDRESS_1028380] X† STREET Profiling of tissue
X 6.[ADDRESS_1028381] not be older than 2 months at 
time of molecular profiling
 X 
Staging determined; when applicable, protocol-directed 
standard care tx recommendations provided to treating MD
X *Standard           
Care     ActivitesMost 
RecentCBC with differential including 
platelet count and hemoglobin 
dALT/SGPT, AST/SGOT, AlkP,  total 
bilirubin , GFR or creatinine     X 
X X 
X 
 X  X collect prior to start of therapy                                    
(x) = may collect at OR and/or at any restageAT Coordinating SITE ONLY                 
Blood for research                         
   ◘Imaging:  PET & MRI  (per MD discretion) (standard care activity) 
November 24, 2015, Amendment 13  36 
 7. ASSESSMENT OF ACTIVITY  
7.1. Definition of Treatment Response 
 Response to neoadjuvant therapy will be assessed at the time of restaging and recorded as:  
1.   Clinical benefit: defined as stable or improved performance status 
2.  Biochemical benefit:  defined as a stable or lower Ca19 -9 in those patients whose Ca19 -9    was 
abnormal at the start of therapy 
3.  Radiographic benefit:  the absence of disease progression and a primary tumor which is  smaller 
(as assessed by [CONTACT_751201])  
All patients who receive at least [ADDRESS_1028382] scan  of the abdomen/pelvis and CT of chest or 
Chest X -ray. Treatment response will be classified by [CONTACT_404343] 1.1 criteria (see Appendix G). 
In addition, tumors will be assessed for conversion of tumor from borderline resectable to resectable 
based on previously defined criteria.  For progression that is operable vs. inoperable progression see 
sections 3.1.2., 3.1.3., and 3.1.4.  
7.2.2. PET-S can Imaging 
 18F-FDG PET scans from the coordinating site will be evaluated semi quantitatively  by [CONTACT_751202]. 
SUV’ s normalized  to injected activity, patient's body weight and hyper metabolic  activity in the 
cerebellum will be calculated from the mean activity concentration in the tumor VOIs between [ADDRESS_1028383] time frame of the dynamic scan. A volume-weighted mean value of 
each PET scan will be derived fro m all lesions to give one average SUV (SUV avg) for each PET scan. The 
percentage change in SUV between the 18F-FDG PET at baseline and at completion of neoadjuvant 
therapy will be calculated .  PET scans are per physician discretion.   
7.2.3. Diffusion Weighted MRI Imaging  
 A t the coordinating site, diffusion-weighted MRI of the abdomen will be performed by a 
commercially available 3.[ADDRESS_1028384] timing of the early arterial, late arterial/parenchymal and venous phase. Diffusion weighted 
imaging will also be performed . Apparent diffusion coefficient (ADC) maps will be generated by [CONTACT_751203]. The ADC map will be used to determine the hyper cellular/malignant portions of the tumor. Tumor response assessments will be made based on the 
anatomic and functional comparison of the tumors before and after therapy.  MRI’s per physician 
discretion.  
7.2.4. Biochemical T esting  
 Ca19-9 will be evaluated serially in all patients with documented elevated Ca19- 9 at initial screening . 
The Ca 19-9 value documented at  study inclusion and subsequent staging is considered reliable 
(evaluable)  when bilirubin is <2.  
7.3. Survival  
 PFS will be calculated only in patients who underwent resection, from the date of cytologic or 
histologic diagnosis until the date of recurrenc e or the last date at which the patient was known to be free 
of disease.  OS will be calculated from the date of cytologic or histologic diagnosis until the date of death or last contact .  
 OS and PFS will be calculated on all treated patients. Patients without disease progression at [ADDRESS_1028385]-study therapeutic surgery/resection or radiation prior to progression will be censored at the initiation of that therapy if all macroscopic evidence of the tumor was resected. The date of progression will be the earlier of the dates of progression determined by [CONTACT_364132] (increased 
lesion size, new metastases, new arterial/venous involvement) and rising Ca19 -[ADDRESS_1028386] medical occurrence temporally associated with any 
study procedure or treatment, regardless of whether it is considered related to the study procedure or 
treatment . This includes changes in laboratory parameters. The National Cancer Institute Common 
Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.0 will be used to grade adverse events (see 
June 28 2018, Amendment 18 38 Appendix C). All unexpected grade 3 and all grade 4-5 adverse events (AE) occurring during the study 
protocol will be recorded, noting  severity and causality . AE’s will be collected in a summary format as 
delineated in the study calendar (sections 6.6 and 6.7).  
8.1.2 Reporting Adverse Events (AE)  
 AEs will be recorded in OnCore and an alert of a new AE will be sent to the multicenter study 
coordinator.  AE reporting to the IRB will be per policy of the approving IRB ( for the coordinating site, 
see Appendix D Medical College of Wisconsin Office of Research SOP Requirements for Reporting to 
the IRB) .  See Appendix N for the communication plan for participating site reporting of SAE’s to 
the coordinating site.  
8.2. Serious Adverse Events (SAEs) 
 All SAEs , whether or not considered related to a study procedure s or treatments, occurring during the 
study protocol or within [ADDRESS_1028387] 
medical o ccurrence that results in: (1) death including all deat hs occurring within [ADDRESS_1028388] 
treatment administration,  (2) life -threatening events, (3) events requiring hospi[INVESTIGATOR_40026], or (4) events which are incapacitating, or permanently disabling. Medically important 
events t hat may not be immediately life -threatening, or result in death or hospi[INVESTIGATOR_059], but may 
jeopardize the patient or require intervention to prevent one of the other listed above outcomes, will be 
considered serious. If the patient dies, any post- mortem f indings including histopathology must be 
provided. SAE reporting to the IRB will be per policy of the approving IRB. See Appendix N for the 
communication plan for participating site reporting of SAE’s to the coordinating site.  
8.3. Study Risks 
 The known risk associated with participating in this study is similar to the risk of standard care. All 
activities of the study are standard care except for the risks of obtaining extra  passes during the  EUS/FNA 
(at screening), and obtaining up to 10 blood dra ws of 30  cc of extra blood at several time points  during 
the study.  Research blood will be obtained only for subjects enrolled at the coordinating site.  
8.3.1. Known Risks  
The slight  risk of extra passes during FNA represents an increase in the already standing risks 
associated with EUS/FNA. Because this study takes extra samples during the routine FNA procedure, the 
extra risks of the research are the additional side effects that could occur because the procedure will last a few minutes longer and because the FNA will require several additional samples.  
June 28 2018, Amendment 18 39  Less frequent side effects related to EUS include drug reaction from medication for sedation, 
irritation and/or tenderness at the site of sedative injection, including the rare chance of clotting at the vein. A rare side effect of EUS is perforation of the GI tract requiring surgical repair .  
 Less frequent side effects of FNA include infection . Rarely , pancreatitis  can occur and usually 
resolves with conservative treatment  within a few days. Very rarely, surgery would be required for 
pancreatitis . Another rare side effect of FNA is minor bleeding where the needle is passed through the gut 
wall. Very rarely, unusual bleeding may require hospi[INVESTIGATOR_5478]/or blood transfusion and/or surgery.   
8.3.2. Risk Discussion  
 This study is assessing a treatment approach . It is not assessing safety or efficacy of the individual 
therapi[INVESTIGATOR_014]. This study is isolating a prescriptive approach (molecular profiling) that relies on clinical application of the results of studies involving tumor biomarkers (targets) to identify best treatments.  The major risk is that conclusions from recent scientific studies (focused on treating the individual pancreatic 
tumor based on biomarkers specific to the tumor itself) will not support treatment decisions equally or 
better than the earlier scientific studies that were focused on the treatment response of groups of patients and that are currently use d by [CONTACT_751204] . The 
prescriptive approach that is the focus of this study is currently used as standard care by [CONTACT_751205] (such as academicians who stay current with recent research), yet this prescriptive use is disparate within the larger oncology community, thus requiring future research.  
 The discussion of risk (other than the risks of blood draw and extra passes during FNA), therefore, falls to the oncologist’s standard discussion of risk with his/her patient when prescribing the FDA -
approved treatment that is identified as the appropriate treatment.  
8.4. Study Benefits 
 This is a new treatment approach , and the exact degree of efficacy is unknown. The patient may 
benefit from participating in this study by [CONTACT_7661] a better chance of successful resection of his/her tumor .  
The knowledge gained from this study may benefit future patients with pancreatic adenocarcinoma.  
9. PATIENT DISCONTINUATION  
 If an investigator removes a patient from the study or if the patient declines further participation, a 
final assessment of the patient’s disease status should be performed prior to any therapeutic intervention . 
These results, along with a reason for study discontinuation will be recorded. The status of a patient who is discontinued for purposes other than recurre nt or metastatic disease  should be monitored in on-study 
follow-up (see Section 6.5) whenever possibl e as long as the patient agrees. Patients will discontinue 
June 28 2018, Amendment 18 40 treatment if any of the following occur: (1) recurrent or metastatic disease, (2) unacceptable t oxicity, (3) 
patient withdrawal of consent, (4) investigator decision, or (5) non- compliance.  
10. DISCONTINUATION OF THE STUDY  
 The entire trial will be stopped if evidence has emerged that makes the study continuation 
unnecessary or unethical or when  the stated objectives are achieved .  
11. STATISTICAL METHODS  
 Assumptions: 
1.   60% of the patients are borderline resectable  
2.   Resectable patients have a resectability rate of 80% 
3.   Borderline resectable patients have a resectability rate of 60% 
4.   Two -sided  5% significance level, 80% power  
 Assumptions for effect on survival  
1. The median survival is 40 months for those who are resected, and 12 months for those who are not 
resected.  
2.    Exponentially distributed survival time for resected and non- resected patients.  
 Some implications:  
1.    The overall resectability rate is 69% 
2.    Median survival of all resectable patients is 23.7 months  
3.    Median survival of all borderline resectable patients is 18.3 months  
4.    Median survival of all patients is 2 0.2 months  
5.    170 historical controls  
6.    120 study subjects  
7.    Primary outcome: resectability rate  
8.    Secondary outcomes: overall survival, progression- free survival  
 
     The proportion of patients whose tumors are successfully resected will be compared between the 
historical controls and the experimental group via a Mantel- Haenszel test with two strata: resectable 
tumors and borderline resectable tumors. We expect 60% of t he patients to fall into the borderline 
June [ADDRESS_1028389] an 80% power to detect an increase in resectability if the true odds ratio is 2.35.. This corresponds to an increase of resectability from 60% to 78 % for borderline resectable patients, and from 80 % to 90% for 
resectable patients, and a 85%  overall rate of resectability.  
 Assuming that all the gains for survival will be from moving patients from the non -resected to the 
resected group, and that survival has an exponential distribution, the median survival should improve from 23.[ADDRESS_1028390]; time to progression will be calculated only in patients who underwent resection, from the date of cytologic or histologic diagnosis until the date of recurrence or the last date at which the patient was known to be free of disease. The survival curves will be estimated using the Kaplan- Meier 
method, and the two groups will be compared via a stratified log- rank test at a two -sided 5% significance 
level.  
12. ADJUNCT TRANSLATIONAL  STUDIES  at Coordinating Site only  
12.1. Generation of Direct Xenograft Tumors 
12.1.1. Rationale 
     The identification of the molecular targets prior to treatment allows for the selection and early delivery 
of optimal therapeutic regimens . While response to therapi[INVESTIGATOR_751178], it 
is still unclear which individual targets may be of greatest therapeutic value. In order to address this 
problem, we propose to implant human pancreas tumors in mice. By [CONTACT_9851] a renewable xenograft model from resected human tumors, tumor samples can be expanded and characterized in depth at the genetic and epi[INVESTIGATOR_243035]. The major advantage of utilizing human pancreatic xenografts lies in the ability of the tumor to maintain an identical genetic and morphological phenotype to the primary tumor. In addition, it appears that no major variations in the status principal genes are mutated through early passaging of car cinoma in mice, suggesting that the fundamental pathogenetic elements remain 
stable.
25This murine model can be used to apply, test, and validate novel treatment regimens . Therefore, 
the efficacy and pharmacodynamic effect of multiple single treatments or c ombination of treatments on a 
single tumor may be examined in manner which may not be feasible in a clinical trial setting . 
Furthermore, the xenograft models may be used to study other aspects of tumor biology including angiogenesis, tumor microenvironment , and cancer stem cells.  
June 28 2018, Amendment 18 42  This protocol provides us with an opportunity to assess the feasibility of generating xenografts of 
resected and metastatic tumors. To generate human pancreatic cancer xenografts we would utilize a 
previously described method, whi ch reported engraftment rates ranging from 20-100%.3 In this model, 
fresh human tumors are either implanted into immunodeficient mice in an orthotopic or heterotopic 
fashion . The tumors are then expanded and may be stored for further use. The p rimary determinants of 
successful tumor engraftment are related to the viability, sterility, and processing time of the specimen. This protocol will allow us the opportunity to implement and further refine the procurement and 
processing of resected tumors to optimize xenograft engraftment.  
12.1.2. Murine Model  
 NOD/SCID mice will be utilized in the generation of xenograft tumors as this model has been 
demonstrated to have superior efficiency of tumor formation. The mice will be housed in specific 
pathogen-free conditions to prevent sickness and infectious outbreak. After implantation the mice will be monitored regularly for general health and weekly body weights will be obtained. All animal- related 
protocols will be submitted for the Institutional Animal Ca re and Use Committee (IACUC) review and 
approval. See Laboratory Manual : Section 3 for details of tumor engraftment and expansion  (Appendix 
J).  Laboratory procedures may be revised as required to maximize processing quality.  
12.2. Characterization of Resected Primary & Metastatic Tumors 
12.2.1. Rationale 
 The expected CR response after neoadjuvant chemo radiotherapy for pancreatic cancer is 
approximately 1% . Even in the setting of favorable clinicopathologic features such as node negativity and 
negative margins, the majority of pancreatic cancers will recur. Following completion of neoadjuvant 
therapy, the residual viable tumor present in the rese cted primary specimen may represent a population of 
cells which are resistant to the administered therapy . Further characterization of the residual primary 
tumor may improve future treatment options for inevitably recurrent disease.  Patients who develop metastatic disease may be candidates for biopsy or resection of these 
lesions . Further analysis of metastatic lesions may potentially provide important information regarding 
the pathogenesis of genetic alterations which are associated with pancreatic cancer metastases or molecular biologic correlates of adjuvant therapy failure. Importantly, unlike previous rapid autopsy series, resection of evolving metastatic lesions allow for further insight into the temporal sequence of genetic alte rations leading to cancer metastases and death. This protocol will allow patients to have 
repeated characterization of primary and metastatic tumors.  
12.2.2. Molecular C haracterization of P rimary R esected and Metastatic T umors  
June 28 2018, Amendment 18 43  Residual and metastatic tumo rs will be assessed for phenotypic changes in histology. In addition, 
using IHC and quantitative real -time polymerase chain reaction (qRT PCR), the resected tumors will 
undergo molecular characterization of the previously tested targets: SPARC, RRM1, ERCC1 , TYMS, 
TOP1 and hENT1 . The initial tumor molecular phenotype will be compared to the subsequent resected 
tumor molecular phenotype to evaluate for changes suggestive of new chemotherapeutic resistance.  
12.2.3. Biomarkers in peripheral blood  
 Inherent in the tumor biology of cancer, cells or cell components may be found within the blood 
stream prior to gross identification of metastatic disease either with radiographic techniques or at the time of surgery. We hypothesize that prior to the devel opment of metastatic disease, circulating tumor cells or 
exosomes may be identified.  Using peripheral blood samples from patients at different stages of treatment, we plan to assess for changes in circulating tumor cell numbers.  In addition, we will eval uate 
changes in exosomal microRNA expression within patient serum as it relates to treatment and prognosis.  
Finally, we seek to be able to identify the presence of cell- free DNA as a marker of tumor stage and 
prognosis from patient plasma. 
13. ADMINISTRATION  
13.1. Training 
 Investigator and staff training will be conducted to share information regarding study design, study 
requirement s and amendments subsequent to study onset. 
13.2. Multi -site Approval and Activation 
The Multi -Site Research Coordinating Office is responsible for oversight of regulatory documentation for 
each Participating Institution(s).  Documents should be provided to the MCW CTO Coordinating Office 
either via the OnCore Clinical Trials Management System (CTMS) or by [INVESTIGATOR_89472] ([PHONE_15660].  For questions, please call ([PHONE_15661].  See address and contact [CONTACT_3031];   
CCCTO Multi -Site Research Coordinating Office  
Medical College of Wisconsin/Cancer Center  
[ADDRESS_1028391] 
Milwaukee, WI  [ZIP_CODE] 
Phone-([PHONE_15662] Fax- ([PHONE_15660] 
[EMAIL_14348]  
 
June 28 2018, Amendment 18 44 See Appendix N for Procedures related to Multi-site Approval, Activation , Site Monitoring, and Ongoing 
Management  
13.2.1 Site Initiation  
 Site initiation will be performed to assure that each Investigator and his/her staff understand the 
protocol, applicable regulations, human subject protections requirements, and the Investigator’s 
obligations.  The site initiation process will ensure that required documentation with the appropriate 
approval i s in place prior to subject enrollment.  
13.2.2 Monitoring  
 The Medical College of Wisconsin Cancer Center Clinical Trials Office will provide monitoring for 
this study.  The monitor(s) is qualified by [CONTACT_751206] s ite to ensure continuing adequacy of facilities and adherence to the clinical study 
protocol, and applicable regulations and laws that pertain to the conduct of the clinical study.  The monitor(s) will review the data collection and source documentation, the timely subm ission of accurate 
records to the Sponsor, and the maintenance of proper records.  A report will be written following site monitoring and a follow-up letter will be provided with a summary of findings.  
13.[ADDRESS_1028392] and enter the data int o an electronic database. Source 
documents, o riginal reports and films, will remain  in each respective institution’s medical record s for 
future reference.  Data will be collected according to r esearch activities specified in Protocol Sections 6.[ADDRESS_1028393]-specific Research Files (SsRF), maintained on site, will include study- specific source 
documents such as the Enrollment Checklist, the o riginal signed consent and any additional source notes 
obtained by [CONTACT_2710].  In addition, the SsRF will include copi[INVESTIGATOR_14168] (such as 
copi[INVESTIGATOR_751179]) as specified in Appendix N.  (See 
Appendix N for procedures regarding maintenance of Subject Research File). 
June 28 2018, Amendment 18 45  All study records and source data will be available for inspection by [CONTACT_751207](s), IRB and other regulatory authorities.  The coordinating site and the participating site  will 
record data associated with assessment of the primary objective ; certain data associated with secondary 
objective s may be collected for patients enrolled only at the coordinating site (as noted by [CONTACT_751208] 2.1.2 Secondary Objectives).  Once entered, data will be evaluated to ensure that it is complete, 
consistent and logically sound.  If changes to the data are required, all changes, reason for changes and 
persons making the changes will be documented.  
13.6. Data Safety Monitoring  
 This study will be monitored by [CONTACT_751209]/MCW  Cancer Center Data Safety Monitoring Committee 
(FH/MCW CC DSMC ).  A record of the membership of the FH/MCW CC DSMC  will be maintained in 
the study research file and updated when membership changes . The FH/MCW CC DSMC  will review 
DSM reports from the study PI [CONTACT_31576] -annually or more frequently if needed.  
 Patients will be  monitored throughout the course of therapy for  toxicity . Safety evaluations will 
consist of physician s and/or their designees’ assessments and examinations and laboratory measurements 
prior to initiating ea ch cycle of chemotherapy . For purposes of DSMB reporting, adverse events will be 
described and graded according the NCI Common Toxicity Criteria version 4.03 ( see Appendix C). 
A summary of the FH/MCW CC DSMC activities are as follows:  
• Review the clinical trial for data integrity a nd safety.  
• Review all unexpected grade 3, and all grade 4, and 5 adverse events, as well as any others 
requiring expedited reporting as defined in this protocol. (Grades 4 & [ADDRESS_1028394] be reported 
to the DSMC within 5 calendar days of study staff’s knowledge.)  
• Grade 4 (life threatening) hematologic toxicities are reported every 6 months. All other grade 4 
toxicities (life threatening) are reported within 5 calendar days.   
• Review all DSM reports.  
• Submit a summary of any recommendations related to study conduct.  
• Terminate the study if deemed unsafe for patients.  
 
A copy of the MCWCC Data and Safety Monitoring Plan and membership roster will be maintained in 
the study research file and updated as membership changes. The committee will review reports from the 
study PI [INVESTIGATOR_182168] (or more frequently if needed) and provide recommendations on trial 
continuation, suspension or termination as necessary.   
Any available DSMC letters will be submitted to the IRB of record as required.  
 The participating site will submit DSMB reports to the Coordinating site, and the Coordinating site 
will forward all reports  to the DSMB.  
June [ADDRESS_1028395] of the study to be 
fully documented and the study data to be subsequently verified. The patient’s involvement in the study 
should be clearly documented in the clinical records. Details are to include the protocol number, the patient’s identification number, the patient’s consent(s)  to take part in the study, the date of all study visits 
and the dates of treatment. Copi[INVESTIGATOR_751180], for as long as legally required after completion of the study . All study data including master files, CRFs, source data, and 
correspondence with the Coordinating site , an IRB, or study subject will be stored for at least 10 years 
according to MCW Office of Research SOP (see Appendix E).  
 Clinical study records will not be dispos ed of, nor custody of the records transferred, without prior 
Coordinating site approval. 
13.8. Ethics Consideration 
 The study must be approved by [CONTACT_751210] H uman Research Protection . The investigators will inform the 
IRB of subsequent protocol amendments. 
 The investigator must inform the patient about the background and present knowledge of treatment 
via molecular profiling. The investigator must ensure the following items are discussed:  
1.    The patient must be provided the patient information and informed consent form consistent with 
the protocol version used and approved by [CONTACT_1201] . The patient must be informed that this is a new 
treatment approach and that the exact degree of efficacy is unknown, and that treating him/her will 
contribute to further knowledge.  
2.    The patient will be given time to discuss his/her participation with the investigator and members of 
their fami ly. Before the patient is entered into the study, the patient’s written consent must be 
obtained. A copy of the signed consent form will be provided to the patient and the original scanned 
into the electronic database created for this study.  
3.    The patient  may refuse to provide a biopsy or may refuse treatment proposed in the context of the 
study before or at any time during the study. Refusal to participate will involve no penalty or loss 
of benefits to which the patient is otherwise entitled.  
4.    An explan ation of whom to contact [CONTACT_751211]’s rights, and who to contact [CONTACT_44751] a research- related injury must be given to the 
patient.  
June 28 2018, Amendment 18 47 13.9. Publication Policy 
 All the results are the property o f the Principal investigators . Investigators may not submit for 
publication or presentation study results without allowing the PIs 30 working days to review and 
comment on the pre -publication manuscript. Co -authorship will be discussed and mutually agreed upon 
before submission  of a manuscript to a publisher. 
  
November 24, 2015, Amendment 13  48 
 Figure A 
 

June 28 2018, Amendment 18 49 Figure B  
 

June 28 2018, Amendment 18 50 Figure C  
  

June 28 2018, Amendment 18 51  
  Resection Profiling (previous neoadj XRT ) 
TYMS high & RRM1 high or 
hENT1 - or Target not Identified  
Gem(- )/5FU(-)  TYMS low & RRM1 high or hENT1 - 
Gem(- )/5FU(+)  GTYMS high & RRM1 low & hENT1 +  
Gem(+)/5FU(-)  
Gem/Platin  FOLFIRINOX  Gem/nab  Figure D  
FOLFIRI  5-FU Gem/Irino  Gem  Profile Not Predictive  
ERCC 
expressn  
- 
 + 
TOPO 
expressn  
- 
 + 
SPARC 
expressn  
- 
 + 
ERCC 
expressn  
- 
 + 
TOPO 
expressn  
- 
 + 
SPARC 
expressn  
- 
 + 
Cape/nab  
SMAD 
expressn  
- 
 + 
Gem/Cape  No further 
Rx 
Target not identified: 4 mo Gem/Cape  TYMS low & RRM1 low & hENT1 +  
Gem(+)/5FU(+)  
Gem/Cap  FOLFIRINOX  
ERCC 
expressn  
- 
 + 
SPARC 
expressn  
- 
 + 
Gem/nab  
TOPO 
expressn  
- 
 + 
FOLFIRI vs. 
Gem/Irino  

June 28 2018, Amendment 18 52 Figure E
 

November 24, 2015, Amendment 13  53 
 Appendices A  – M ( see separate Appendices document) 
  
June 28 2018, Amendment 18 54 14. REFERENCES 
 
1. Katz MHG, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA,  Varadhachary G, 
Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pi[INVESTIGATOR_327771], 
Evans DB. Long- term survival after multidisciplinary management of resected pancreatic 
adenocarcinoma. Ann Surg Oncol. 2009; 16(4):836-4 
2. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based 
chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin 
Oncol. 2008; 26(21):3496-502). 
3. Akita H, Zheng Z, [COMPANY_005] Y et al. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene. 2009; 28: 2903-2909. 
4. Kuppens I, Beijnen J and Schellens J. Topoisomerase I inhibitors in the treatment of 
gastrointestinal cancer:  from intravenous to oral administration. Clin Colorectal Cancer. 
2004; 4(3):  163-180. 
5. Chen G, Tian X, Liu Z et al. Inhibition of endogenous SPARC enhances pancrea tic cell 
growth:  modulation by [CONTACT_751212]1-III isoform expression. Brit J Cancer. 2010; 102:  188-
195.  
6. Rejiba S, Bigand C, Parmentier C et al. Gemcitabine -based chemogene therapy for 
pancreatic cancer using Ad -dCK :UMK GDEPT and TS/RRsiRNA strategies. Neoplasi a. 
2009; 11(7):  637-650. 
7. Iacobuzio -Donahue Christine A, Fu Baojin, et al.  DPC4 Gene Status of the Primary 
Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer.  J Clin 
Oncol. 2009;27(11):1806-1813. 
8. Crane Christopher H, Varadhachary, Gauri R, et al.  Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by [CONTACT_751213] (Tr) Pancreatic Adenocarcinoma:  Correlation of Smad4 (Dpc4) 
June 28 2018, Amendment 18 55  
Immunostaining With Pattern of Disease Progression.  J Clin Oncol. 2011;29(22):3037-
3043.  
9.  Katz MHG, Pi[INVESTIGATOR_327771], Evans DB et al.  Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.  J Am Coll Surg 2008; 206(5):833-46; discussion 846-8. 
10. Keim R, Rao
 A, Von Hoff  D, Evans DB, Christians  KK.  Molecular Profiling of 
Endoscopic Ultrasound (EUS) – Guided Fine Needle Aspi[INVESTIGATOR_1516] (FNA) specimens in pancreas cancer:  A feasibility study. Pancreas Club, Chicago, Ill; May 6-7, 2011. 
11. Evans DB, Christians KK and Foley WD. Pancreatectomy (Whipple Operation) and Total Pancreatectomy for Cancer. Mastery of Surgery 6
th Ed. Fischer JL Ed. Wolters 
Kluwer/Lippi[INVESTIGATOR_751181] & Wilkins, Philadelphia 2012; 1445-1466. 
12. Staley CA, Cleary KR, Abbruzzese, ML, et al. The need for standardized  pathologic 
staging of pancreaticoduodenectomy specimens. Pancreas 1996; 12(4): 373-380.  
13. De Paoli A, Chiara S, Luppi G et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer:  a multicentric p hase II 
study. Ann Oncol 2006; 17: 246-251. 
14. Conroy T, Desseigne F, Ychou M, et al. FNCLCC-FFCD PRODIGE Group. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 28:15s, 2010 (suppl; abstr 4010). 
June 28 2018, Amendment 18 56  
15. Van Rijswijk RE, Jeziorski K, Wagener DJ, Van Laethem JL, Reuse S, Baron B, Wils J, 
Weekly High -Dose 5 -fluorouracil and Folinic Acid in Metastatic Pancreatic Carcinoma :  
A Phase II Study of The EORTC GastroIntestinal Tract Cancer Cooperative Group. Eur J Cancer. 2004;40(14):2077. 
16. Rocha Lima CM, Green MR, Rotche R et al.  Irinotecan p lus gemcitabine results in no 
survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despi[INVESTIGATOR_414451].  J Clin Oncol 2004 ; 22(18) :3776-3883. 
17. Louvet C, Labianca R, Ha mmel P,  et al. Gemcitabine in combination with oxaliplatin 
compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: 
results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005, 23(15):3509-3516 
18. Varadhachary GR, Wolff RA, Crane CH et. al. Preoperative gemcitabine and cisplatin 
followed by [CONTACT_35421]- based chemoradiation for resectable adenocarcinoma of the 
pancreatic head. J Clin Oncol. 2008; 26(21): 3487-3495. 
19. Herrmann R, Bodoky G, Ruhstaller T et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer:  a randomized, multicenter, phase iii trial of the Swiss group for clinical cancer research and the central European cooperative oncology group. J Clin Oncol 2007; 25(16):  2212-2217. 
20. C. Neuzillet, O. Hentic, B. Rousseau, V. Rebours, L. Bengrine-Lefèvre, E. Raymond, P. Ruszniewski, C. Louvet, P. Hammel; Hôpi[INVESTIGATOR_751182], Paris, [LOCATION_009]; Hôpi[INVESTIGATOR_57055], Clichy, [LOCATION_009].  FOLFIRI Regimen As Second- /Third -line Chem otherapy in 
Patients With Advanced Pancreatic Adenocarcinoma Refractory to Gemcitabine and 
June 28 2018, Amendment 18 57  
Platinum Salts  :  A Retrospective Series of 70 Patients. .J Clin Oncol 29: 2011 (suppl 4; 
abstr 272)Cartwright TH, Cohn A, Varkey JA, Chen YM, Szatrowski TP, Cox JV, Schulz 
JJ. J Clin Oncol. 2002;20(1):160. 
21. Von Hoff DD, Ramanathan R, Borad M et al. SPARC correlation with response to gemcitabine plus nab- paclitaxel in patients with advanced metastatic pancreatic cancer  : 
A phase 1/II study. ASCO Proceedings 2009; 27(No. 15S) 208s (abstract #4525). 
22. Somer BG, Schwartzbert, LS, Arena F, Epperson A, Fu D, Bortner B.V.  Phase II Trial of nab-paclitaxel (nanoparticle albumin -bound paclitaxel (ABX)) + capecitabine (XEL) in 
first-line treatment of metastatic breast cancer (MBC) .  Journal of Clinical Oncology, 
2007 ASCOAnnual Meeting Proceedings Part 1. Vol25, No. 18S (June 20 Supplement), 2007: [ADDRESS_1028396]-line therapy for pat ients with advanced pancreatic cancer. J Clin 
Oncol 1997; 15(6): 2403-13. 
24. DeCaprio JA, Mayer RJ, Gonin R, Arbuck SG.   Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas  :  results of 
a phase II trial.  J Clin Oncol. 1991;9(12):2128.   
25. Kamikozuru H, Kuramochi H, Hayashi K et al. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum- based 
chemotherapy. Internat J of Oncol. 2008; 32:  1091-1096. 
26. Friboulet L, Olaussen K, Pi[INVESTIGATOR_119603] J,et al.  ERCC1 Isoform Expression and DNA Repair in 
Non-Small-Cell Lung Cancer.  N Engl J Med. (2013). 
June 28 2018, Amendment 18 58  
  
 